Orally Disintegrating Drug - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511248600

Publication Date:

November 5, 2024

Pages:

114

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
The global market for Orally Disintegrating Drug was estimated to be worth US$ 1957 million in 2023 and is forecast to a readjusted size of US$ 3709.6 million by 2030 with a CAGR of 9.5% during the forecast period 2024-2030
The orally disintegrating drug market is being driven by several factors. One of the primary drivers is the growing demand for convenient and patient-friendly medication delivery methods. Orally disintegrating drugs offer an advantage over traditional oral tablets as they quickly dissolve in the mouth without the need for water, making them easier to administer, particularly for individuals with swallowing difficulties, pediatric patients, and the elderly. Additionally, the increasing prevalence of chronic diseases and the need for efficient and immediate drug absorption have fueled the demand for orally disintegrating drugs. Furthermore, advancements in formulation technologies and taste-masking techniques have improved the palatability of these drugs, enhancing patient compliance. Overall, the demand for orally disintegrating drugs is driven by the need for convenience, improved patient experience, and enhanced drug delivery options in the pharmaceutical market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Orally Disintegrating Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Orally Disintegrating Drug by region & country, by Type, and by Application.
The Orally Disintegrating Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Orally Disintegrating Drug.
麻豆原创 Segmentation
By Company
Johnson and Johnson
GSK
Otsuka
Vartris
Teva
Pfizer
Eli Lilly and Company
Merck
Eisai
AstraZeneca
Bristol-Myers Squibb
Conquer
Segment by Type:
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segment by Application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Orally Disintegrating Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Orally Disintegrating Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Orally Disintegrating Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Orally Disintegrating Drug Product Introduction
1.2 Global Orally Disintegrating Drug 麻豆原创 Size Forecast
1.3 Orally Disintegrating Drug 麻豆原创 Trends & Drivers
1.3.1 Orally Disintegrating Drug Industry Trends
1.3.2 Orally Disintegrating Drug 麻豆原创 Drivers & Opportunity
1.3.3 Orally Disintegrating Drug 麻豆原创 Challenges
1.3.4 Orally Disintegrating Drug 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Orally Disintegrating Drug Players Revenue Ranking (2023)
2.2 Global Orally Disintegrating Drug Revenue by Company (2019-2024)
2.3 Key Companies Orally Disintegrating Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Orally Disintegrating Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Orally Disintegrating Drug
2.6 Orally Disintegrating Drug 麻豆原创 Competitive Analysis
2.6.1 Orally Disintegrating Drug 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Orally Disintegrating Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orally Disintegrating Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Anti-Psychotics Drug
3.1.2 Anti-Epileptics Drug
3.1.3 Other
3.2 Global Orally Disintegrating Drug Sales Value by Type
3.2.1 Global Orally Disintegrating Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Orally Disintegrating Drug Sales Value, by Type (2019-2030)
3.2.3 Global Orally Disintegrating Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 CNS Diseases
4.1.2 Gastrointestinal Diseases
4.1.3 CVS Diseases
4.1.4 Other
4.2 Global Orally Disintegrating Drug Sales Value by Application
4.2.1 Global Orally Disintegrating Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Orally Disintegrating Drug Sales Value, by Application (2019-2030)
4.2.3 Global Orally Disintegrating Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Orally Disintegrating Drug Sales Value by Region
5.1.1 Global Orally Disintegrating Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Orally Disintegrating Drug Sales Value by Region (2019-2024)
5.1.3 Global Orally Disintegrating Drug Sales Value by Region (2025-2030)
5.1.4 Global Orally Disintegrating Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Orally Disintegrating Drug Sales Value, 2019-2030
5.2.2 North America Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Orally Disintegrating Drug Sales Value, 2019-2030
5.3.2 Europe Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Orally Disintegrating Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Orally Disintegrating Drug Sales Value, 2019-2030
5.5.2 South America Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Orally Disintegrating Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Orally Disintegrating Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Orally Disintegrating Drug Sales Value
6.3 United States
6.3.1 United States Orally Disintegrating Drug Sales Value, 2019-2030
6.3.2 United States Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Orally Disintegrating Drug Sales Value, 2019-2030
6.4.2 Europe Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Orally Disintegrating Drug Sales Value, 2019-2030
6.5.2 China Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Orally Disintegrating Drug Sales Value, 2019-2030
6.6.2 Japan Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Orally Disintegrating Drug Sales Value, 2019-2030
6.7.2 South Korea Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Orally Disintegrating Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Orally Disintegrating Drug Sales Value, 2019-2030
6.9.2 India Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Johnson and Johnson
7.1.1 Johnson and Johnson Profile
7.1.2 Johnson and Johnson Main Business
7.1.3 Johnson and Johnson Orally Disintegrating Drug Products, Services and Solutions
7.1.4 Johnson and Johnson Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.1.5 Johnson and Johnson Recent Developments
7.2 GSK
7.2.1 GSK Profile
7.2.2 GSK Main Business
7.2.3 GSK Orally Disintegrating Drug Products, Services and Solutions
7.2.4 GSK Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.2.5 GSK Recent Developments
7.3 Otsuka
7.3.1 Otsuka Profile
7.3.2 Otsuka Main Business
7.3.3 Otsuka Orally Disintegrating Drug Products, Services and Solutions
7.3.4 Otsuka Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.3.5 Vartris Recent Developments
7.4 Vartris
7.4.1 Vartris Profile
7.4.2 Vartris Main Business
7.4.3 Vartris Orally Disintegrating Drug Products, Services and Solutions
7.4.4 Vartris Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.4.5 Vartris Recent Developments
7.5 Teva
7.5.1 Teva Profile
7.5.2 Teva Main Business
7.5.3 Teva Orally Disintegrating Drug Products, Services and Solutions
7.5.4 Teva Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Teva Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer Orally Disintegrating Drug Products, Services and Solutions
7.6.4 Pfizer Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Profile
7.7.2 Eli Lilly and Company Main Business
7.7.3 Eli Lilly and Company Orally Disintegrating Drug Products, Services and Solutions
7.7.4 Eli Lilly and Company Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.7.5 Eli Lilly and Company Recent Developments
7.8 Merck
7.8.1 Merck Profile
7.8.2 Merck Main Business
7.8.3 Merck Orally Disintegrating Drug Products, Services and Solutions
7.8.4 Merck Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.8.5 Merck Recent Developments
7.9 Eisai
7.9.1 Eisai Profile
7.9.2 Eisai Main Business
7.9.3 Eisai Orally Disintegrating Drug Products, Services and Solutions
7.9.4 Eisai Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.9.5 Eisai Recent Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Profile
7.10.2 AstraZeneca Main Business
7.10.3 AstraZeneca Orally Disintegrating Drug Products, Services and Solutions
7.10.4 AstraZeneca Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.10.5 AstraZeneca Recent Developments
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Profile
7.11.2 Bristol-Myers Squibb Main Business
7.11.3 Bristol-Myers Squibb Orally Disintegrating Drug Products, Services and Solutions
7.11.4 Bristol-Myers Squibb Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.11.5 Bristol-Myers Squibb Recent Developments
7.12 Conquer
7.12.1 Conquer Profile
7.12.2 Conquer Main Business
7.12.3 Conquer Orally Disintegrating Drug Products, Services and Solutions
7.12.4 Conquer Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.12.5 Conquer Recent Developments
8 Industry Chain Analysis
8.1 Orally Disintegrating Drug Industrial Chain
8.2 Orally Disintegrating Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Orally Disintegrating Drug Sales Model
8.5.2 Sales Channel
8.5.3 Orally Disintegrating Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Johnson and Johnson
GSK
Otsuka
Vartris
Teva
Pfizer
Eli Lilly and Company
Merck
Eisai
AstraZeneca
Bristol-Myers Squibb
Conquer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.